Stoke Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Stoke Therapeutics, Inc. (STOK) reported Capital Expenditures Incurred but Not yet Paid of $250.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-03
- Stoke Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$84.00K, a 450.00% decline year-over-year.
- Stoke Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $334.00K, a 1137.04% increase year-over-year.
- Stoke Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $390.00K, a 680.00% increase year-over-year.
- Stoke Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $41.00K, a 272.73% increase year-over-year.
- Stoke Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2025 was $482.00K, a 690.16% increase from fiscal 2024.
- Stoke Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2024 was $61.00K.
- Stoke Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Stoke Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $121.00K, a 90.45% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$84.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $250.00K 10-Q · filed 2026-08-03 | $640.00K derived: sum of 3 quarters · filed 2026-08-03 | $681.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $334.00K 10-Q · filed 2026-05-07 | $724.00K derived: sum of 2 quarters · filed 2026-05-07 | $765.00K derived: sum of 3 quarters · filed 2026-05-07 | $789.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $390.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $431.00K derived: sum of 2 quarters · filed 2026-03-16 | $455.00K derived: sum of 3 quarters · filed 2026-08-03 | $482.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $65.00K derived: sum of 2 quarters · filed 2026-08-03 | $92.00K 10-Q · filed 2025-11-04 | $142.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $51.00K 10-Q · filed 2026-08-03 | $101.00K derived: sum of 3 quarters · filed 2026-08-03 | $112.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $27.00K 10-Q · filed 2026-05-07 | $77.00K derived: sum of 2 quarters · filed 2026-05-07 | $88.00K derived: sum of 3 quarters · filed 2026-05-07 | $82.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $61.00K derived: sum of 2 quarters · filed 2026-03-16 | $55.00K derived: sum of 3 quarters · filed 2026-03-16 | $61.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $5.00K derived: sum of 2 quarters · filed 2025-11-04 | $11.00K 10-Q · filed 2025-11-04 | |
| 2024-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $6.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-03-25 | |||
| 2023-03-31 | $545.00K 10-Q · filed 2024-05-06 | $260.00K derived: sum of 2 quarters · filed 2024-05-06 | -$88.00K derived: sum of 3 quarters · filed 2024-05-06 | $365.00K derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$285.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$633.00K derived: sum of 2 quarters · filed 2024-03-25 | -$180.00K derived: sum of 3 quarters · filed 2024-03-25 | $121.00K 10-K · filed 2024-03-25 |
| 2022-09-30 | -$348.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $105.00K derived: sum of 2 quarters · filed 2023-11-07 | $406.00K 10-Q · filed 2023-11-07 | $1.64M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $453.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $754.00K 10-Q · filed 2023-08-07 | $1.98M derived: sum of 3 quarters · filed 2023-08-07 | |
| 2022-03-31 | $301.00K 10-Q · filed 2023-05-04 | $1.53M derived: sum of 2 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $1.27M 10-K · filed 2023-03-06 | ||
| 2021-09-30 | $38.00K 10-Q · filed 2022-11-14 | |||
| 2021-03-31 | $97.00K 10-Q · filed 2022-05-10 | $27.00K derived: sum of 2 quarters · filed 2022-05-10 | $63.00K derived: sum of 3 quarters · filed 2022-05-10 | $68.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$34.00K derived: sum of 2 quarters · filed 2022-03-10 | -$29.00K derived: sum of 3 quarters · filed 2022-03-10 | $6.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $36.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $41.00K derived: sum of 2 quarters · filed 2021-11-08 | $76.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $40.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | $35.00K 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $140.00K 10-K · filed 2021-03-09 | |||
| 2019-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $236.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $198.00K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $19.00K 10-K · filed 2020-03-23 | |||
| 2018-06-30 | $91.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |